Evidence map›Paper›PMID 30121895›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2019

Quantifying SV2A density and drug occupancy in the human brain using [

Michel Koole, June van Aalst, Martijn Devrome, Nathalie Mertens, Kim Serdons, Brigitte Lacroix, Joel Mercier, David Sciberras, Paul Maguire, Koen Van Laere

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 1 pooled it
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 1 synthesis or guideline pooled it, 139 citations in OpenAlex.

  1. Pooled it
  2. Changes in synaptic density in the subacute phase after ischemic stroke: AJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2022
    Trial
  3. First-in-Human Evaluation ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021
    Trial
  4. Article
  5. Article
  6. Detection of Focal Lesions in Epilepsy with [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Imaging Synaptic Density in Aging and Alzheimer Disease with [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Article
  11. Review
  12. Noninvasive quantification of [European journal of nuclear medicine and molecular imaging · 2024
    Article
  13. SV2A PET shows hippocampal synaptic loss in cognitively unimpaired APOE ε4/ε4 homozygotes.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  14. Article
  15. Synaptic changes in psychiatric and neurological disorders: state-of-the art of in vivo imaging.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Review
  16. Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Review
  17. Assessment of cerebral drug occupancy in humans using a single PET-scan: A [European journal of nuclear medicine and molecular imaging · 2024
    Observational
  18. The associations between synaptic density and "A/T/N" biomarkers in Alzheimer's disease: AnJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2024
    Article
  19. Evaluation of [EJNMMI research · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Michel KooleDepartment of Nuclear Medicine and Molecular Imaging, KU Leuven, Herestraat 49, 3000, Leuven, Belgium. michel.koole@kuleuven.be.
June van AalstDepartment of Nuclear Medicine and Molecular Imaging, KU Leuven, Herestraat 49, 3000, Leuven, Belgium.
Martijn DevromeDepartment of Nuclear Medicine and Molecular Imaging, KU Leuven, Herestraat 49, 3000, Leuven, Belgium.
Nathalie MertensDepartment of Nuclear Medicine and Molecular Imaging, KU Leuven, Herestraat 49, 3000, Leuven, Belgium.
Kim SerdonsDepartment of Nuclear Medicine and Molecular Imaging, KU Leuven, Herestraat 49, 3000, Leuven, Belgium.
Brigitte LacroixUCB Pharma, Braine-l'Alleud, Belgium.
Joel MercierUCB Pharma, Braine-l'Alleud, Belgium.
David SciberrasUCB Pharma, Braine-l'Alleud, Belgium.
Paul MaguireUCB Pharma, Braine-l'Alleud, Belgium.
Koen Van LaereDepartment of Nuclear Medicine and Molecular Imaging, KU Leuven, Herestraat 49, 3000, Leuven, Belgium.
KU Leuven · BEUCB Pharma (Belgium) · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeA [

methodsNinety minutes dynamic [

resultsAfter pretreatment, regional V

conclusionThis [

Indexed as

PyridinesPyrrolidinonesAdultFemaleGene Expression RegulationHumansKineticsMagnetic Resonance ImagingMaleMembrane GlycoproteinsMiddle AgedModels, BiologicalMultimodal ImagingNerve Tissue ProteinsPositron-Emission TomographyReference Standards1-((3-(methylpyridin-4-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-oneMembrane GlycoproteinsNerve Tissue ProteinsPyridinesPyrrolidinonesSV2A protein, human[11C]UCB-JKinetic modellingPositron emission tomographyReference tissueSynaptic density

Identifiers

PMID30121895
OpenAlexW2887203046

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.